zonisamide
ApprovedWithdrawn 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Fibromyalgia
Conditions
Fibromyalgia, Migraine
Trial Timeline
Aug 1, 2004 โ Jan 1, 2008
NCT ID
NCT00259636About zonisamide
zonisamide is a approved stage product being developed by Eisai for Fibromyalgia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00259636. Target conditions include Fibromyalgia, Migraine.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01283256 | Pre-clinical | Completed |
| NCT01136954 | Phase 3 | Completed |
| NCT00659958 | Approved | Completed |
| NCT01140867 | Approved | Completed |
| NCT00259636 | Approved | Withdrawn |
| NCT00056576 | Phase 3 | Completed |
Competing Products
20 competing products in Fibromyalgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| ASP8062 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP0819 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Duloxetine | Shionogi | Phase 3 | 77 |
| Duloxetine 60 mg + Placebo | Shionogi | Phase 3 | 77 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Duloxetine | Eli Lilly | Approved | 85 |
| duloxetine hydrochloride + placebo | Eli Lilly | Approved | 85 |
| duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Treatment for Fibromyalgia | Eli Lilly | Pre-clinical | 23 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| Eszopiclone + placebo | Sumitomo Pharma | Approved | 85 |